RSS GSK Reports Headline Results From FIRST-ENGOT-OV44 Phase III Trial - Quick Facts

Currently reading:
 RSS GSK Reports Headline Results From FIRST-ENGOT-OV44 Phase III Trial - Quick Facts

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
10,405
Likes
1,923
Credits
33,567©
Cash
0$
GSK plc (GSK, GSK.L) has disclosed the primary findings from the FIRST-ENGOT-OV44 phase III trial, which assesses the efficacy of Zejula and Jemperli in treating advanced ovarian cancer in the first line. Remarkably, the trial achieved its primary goal of Progression-Free Survival (PFS), showing a statistically significant improvement with the incorporation of dostarlimab alongside the conventional carboplatin-paclitaxel chemotherapy and niraparib maintenance, with the option of including bevacizumab. However, the company noted that the crucial secondary goal of overall survival did not achieve statistical significance.

Hesham Abdullah, Senior Vice President and Global Head of Oncology Research and Development at GSK, commented, "In line with our commitment to advancing treatments in gynecological cancers, we are rigorously exploring the potential of this therapeutic combination and eagerly anticipate unveiling the comprehensive trial findings."

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips

Similar threads

Top Bottom